Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Other hematologic neoplasm 1

Conditions

Leukemia, Myeloid, Acute 64Precursor Cell Lymphoblastic Leukemia-Lymphoma 48Myelodysplastic Syndromes 48Multiple Myeloma 38Lymphoma 37Leukemia 35Lymphoma, Non-Hodgkin 29Leukemia, Lymphocytic, Chronic, B-Cell 24Hodgkin Disease 24Leukemia, Myelogenous, Chronic, BCR-ABL Positive 22Hematologic Neoplasms 18Lymphoma, Large B-Cell, Diffuse 16Primary Myelofibrosis 11Neuroblastoma 11Leukemia, Myelomonocytic, Chronic 11Neoplasms, Plasma Cell 10Myeloproliferative Disorders 10Graft vs Host Disease 10Lymphoma, Follicular 9Leukemia, Biphenotypic, Acute 9Burkitt Lymphoma 8Neoplasms 7Lymphoma, Mantle-Cell 7Leukemia, Myelomonocytic, Juvenile 7Breast Neoplasms 6Rhabdoid Tumor 5Recurrence 5Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 5Lymphoma, T-Cell 5Lymphoma, B-Cell, Marginal Zone 5

Interventions

Cytarabine 7Mitoxantrone 3Cyclophosphamide 3venetoclax 2thymoglobulin 2fludarabine phosphate 2fludarabine 2devimistat 2Thiotepa 2Tacrolimus 2Rituximab 2Melphalan 2Granulocyte Colony-Stimulating Factor 2Filgrastim 2Daunorubicin 2Cladribine 2vosaroxin 1quizartinib 1plerixafor 1pegylated granulocyte colony-stimulating factor 1blinatumomab 1aldesleukin 1Transplantation 1Stem Cell Transplantation 1Sorafenib 1Sirolimus 1Razoxane 1Mycophenolic Acid 1Metformin 1Mesna 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Sarcoma, Myeloid × Stem Cell Transplantation × Clear all
NCT02484391 2024-09-19

CPI-613, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Granulocytic Sarcoma

Wake Forest University Health Sciences

Phase 1 Completed
48 enrolled 13 charts
Other hematologic neoplasmSarcoma

Leukemia, Myeloid, Acute, Sarcoma, Myeloid

Data powered by HemOnc (CC BY 4.0) Colophon âš¡